Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers

Patients with primary breast cancer receiving neoadjuvant letrozole will undergo radiological assessment with digital mammogram, ultrasound (US) including shearwave elastography (SWE). These will be performed at 3 monthly intervals until surgical intervention is considered feasible.

Patients will be receiving neoadjuvant letrozole as standard therapy for breast cancer

Core biopsies will be taken at diagnosis, and at the time of surgery to allow biological assessment of changes in tumour

Breast MRI scans will be performed at time of diagnosis and prior to surgery to allow comparison of MRI change and response to treatment